Rudolf A Werner, Bilêl Habacha, Susanne Lütje, Lena Bundschuh, Takahiro Higuchi, Philipp Hartrampf, Sebastian E Serfling, Thorsten Derlin, Constantin Lapa, Andreas K Buck, Markus Essler, Kenneth J Pienta, Mario A Eisenberger, Mark C Markowski, Laura Shinehouse, Rehab AbdAllah, Ali Salavati, Martin A Lodge, Martin G Pomper, Michael A Gorin, Ralph A Bundschuh, Steven P Rowe
Objectives: In patients with prostate cancer (PC) receiving prostate-specific membrane antigen- (PSMA-) targeted radioligand therapy (RLT), higher baseline standardized uptake values (SUVs) are linked to improved outcome. Thus, readers deciding on RLT must have certainty on the repeatability of PSMA uptake metrics. As such, we aimed to evaluate the test-retest repeatability of lesion uptake in a large cohort of patients imaged with 18 F-DCFPyL. Methods: In this prospective, IRB-approved trial (NCT03793543), 21 patients with history of histologically proven PC underwent two 18 F-DCFPyL PET/CTs within 7 days (mean 3...
2022: Molecular Imaging